Purple Book product · Interchangeable
Poherdy
pertuzumab-dpzb
At a glance
Nov 13, 2025
Approved
Interchangeable
License type
Rx
Marketing
No
Patents listed
Key dates
Approval
Approval date of this BLA submission.
Nov 13, 2025
7 mo ago
Today
Pharmaceutical detail
Strength
420MG/14ML (30MG/ML)
Dosage form
Injection
Route
Intravenous
Presentation
Single-Dose Vial
Center
CDER
License number
2354
Product number
001
Submission type
Original
Supplement number
Not listed
Change type
Not listed
Reference product family
View full familyBiosimilar of pertuzumab (Perjeta)
Patent list (47)
| Patent | Expires | In | Source |
|---|---|---|---|
| 7,862,817 | Jun 01, 2025 | 1 yr ago | FDA |
| 9,017,671 | Oct 19, 2025 | 8 mo ago | FDA |
| 7,449,184 | Mar 12, 2026 | 3 mo ago | FDA |
| 11,034,754 | May 23, 2026 | 12 d ago | FDA |
| 9,631,007 | May 23, 2026 | 12 d ago | FDA |
| 8,404,234 | Jul 03, 2026 | in 29 d | FDA |
| 8,372,396 | Jul 19, 2026 | in 2 mo | FDA |
| 11,261,238 | May 28, 2028 | in 2 yr | FDA |
| 10,808,037 | Jul 08, 2028 | in 2 yr 2 mo | FDA |
| 11,078,294 | Jul 08, 2028 | in 2 yr 2 mo | FDA |
| 11,976,127 | Jul 08, 2028 | in 2 yr 2 mo | FDA |
| 11,987,637 | Jul 08, 2028 | in 2 yr 2 mo | FDA |
| 11,987,638 | Jul 08, 2028 | in 2 yr 2 mo | FDA |
| 11,999,791 | Jul 08, 2028 | in 2 yr 2 mo | FDA |
| 12,098,211 | Jul 08, 2028 | in 2 yr 2 mo | FDA |
| 12,145,997 | Jul 08, 2028 | in 2 yr 2 mo | FDA |
| 12,173,080 | Jul 08, 2028 | in 2 yr 2 mo | FDA |
| 8,574,869 | Jul 08, 2028 | in 2 yr 2 mo | FDA |
| 11,597,776 | Jan 28, 2029 | in 2 yr 8 mo | FDA |
| 12,110,341 | Jan 28, 2029 | in 2 yr 8 mo | FDA |
| 10,689,457 | Jun 15, 2029 | in 3 yr 1 mo | FDA |
| 11,655,305 | Jun 15, 2029 | in 3 yr 1 mo | FDA |
| 9,493,548 | Jun 22, 2029 | in 3 yr 1 mo | FDA |
| 9,181,346 | Jul 18, 2029 | in 3 yr 2 mo | FDA |
| 11,639,395 | Jul 30, 2029 | in 3 yr 2 mo | FDA |
| 10,982,003 | Aug 06, 2030 | in 4 yr 3 mo | FDA |
| 11,225,513 | Aug 06, 2030 | in 4 yr 3 mo | FDA |
| 12,103,975 | Aug 06, 2030 | in 4 yr 3 mo | FDA |
| 9,714,293 | Aug 06, 2030 | in 4 yr 3 mo | FDA |
| 11,414,498 | Dec 23, 2030 | in 4 yr 7 mo | FDA |
| 8,512,983 | Jan 04, 2031 | in 4 yr 8 mo | FDA |
| 10,662,237 | Aug 07, 2031 | in 5 yr 3 mo | FDA |
| 8,652,474 | Sep 28, 2031 | in 5 yr 5 mo | FDA |
| 10,087,237 | Jan 21, 2032 | in 5 yr 9 mo | FDA |
| 10,184,106 | Mar 15, 2033 | in 6 yr 11 mo | FDA |
| 9,493,744 | Feb 24, 2034 | in 7 yr 10 mo | FDA |
| 10,017,732 | Mar 14, 2034 | in 7 yr 11 mo | FDA |
| 10,131,873 | Mar 14, 2034 | in 7 yr 11 mo | FDA |
| 10,676,710 | Mar 14, 2034 | in 7 yr 11 mo | FDA |
| 10,829,732 | Mar 14, 2034 | in 7 yr 11 mo | FDA |
| 9,815,904 | Apr 15, 2034 | in 8 yr | FDA |
| 9,969,811 | Apr 15, 2034 | in 8 yr | FDA |
| 12,145,998 | Sep 07, 2034 | in 8 yr 5 mo | FDA |
| 11,638,756 | Feb 28, 2038 | in 11 yr 11 mo | FDA |
| 12,128,103 | Feb 28, 2038 | in 11 yr 11 mo | FDA |
| 11,077,189 | Mar 14, 2039 | in 13 yr | FDA |
| 11,992,529 | Mar 14, 2039 | in 13 yr | FDA |
Taxonomy and ontology
11 termscenter
Center for Drug Evaluation and Research
center · CDER
application pathway
Biologics License Application
blaNumber · BLA
license type
351(k) Interchangeable
blaType · 351(k) Interchangeable
application pathway
Section 351(k) Biosimilar or Interchangeable
blaType · 351(k)
product role
Interchangeable Biologic
blaType · Interchangeable
marketing status
Prescription
marketingStatus · Rx
licensure status
Licensed
licensure · Licensed
route
Intravenous
routeOfAdministration · Intravenous
dosage form
Injection
dosageForm · Injection
source kind
Monthly Download
sourceKind · monthly_download
- Food and Drug Administrationparent ofCenter for Drug Evaluation and Research
- Food and Drug Administrationsource forMonthly Download
- Biologics License Applicationparent ofSection 351(a) Biologic
- Biologics License Applicationparent ofSection 351(k) Biosimilar or Interchangeable
- Section 351(k) Biosimilar or Interchangeablemaps to351(k) Biosimilar
- Section 351(k) Biosimilar or Interchangeablemaps to351(k) Interchangeable
Source provenance
